百亿A股 重大资产重组

Core Viewpoint - Weigao Blood Purification plans to acquire 100% equity of Shandong Weigao Purui Medical Packaging Co., Ltd. through a share issuance, which is expected to constitute a major asset restructuring and related party transaction [2]. Group 1: Transaction Details - The acquisition is set to be announced on October 17, with trading of the company's stock suspended from October 20, 2025, for a period not exceeding 10 trading days [2]. - Shandong Weigao Purui was established on September 13, 2018, and its business scope includes the production and sales of Class I and II medical devices, as well as the manufacturing of medical packaging materials [2]. Group 2: Shareholding Structure - The counterparties for the transaction include Shandong Weigao Group Medical Polymer Co., Ltd., Weihai Shengxi Enterprise Management Consulting Center (Limited Partnership), and Weihai Ruiming Enterprise Management Consulting Partnership (Limited Partnership) [2]. - Shandong Weigao Group Medical Polymer Co., Ltd. is the largest shareholder of Weigao Purui, holding 94.07% of its shares [3]. Group 3: Company Performance - Weigao Blood Purification was listed on the Shanghai Stock Exchange on May 19 of this year and focuses on the research, production, and sales of blood purification medical products, including blood dialysis devices and solutions [4]. - For the first half of 2025, Weigao Blood Purification reported revenue of 1.765 billion yuan, a year-on-year increase of 8.52%, and a net profit attributable to shareholders of 220 million yuan, up 10.11% year-on-year [8]. - As of October 17, the stock price of Weigao Blood Purification was 38.61 yuan per share, with a market capitalization of 16.13 billion yuan [8].